Abstract
Pharmacogenetics is the inherited basis of differences among individuals in their response to drugs. Genetic polymorphisms of drug-metabolizing enzymes may account for as much as 30% of interindividual differences in drug disposition and response. An increasing number of drug target polymorphisms have also been linked to differences in drug response. This chapter reviews some examples of the use of pharmacogenetics in clinical practice. Despite the increasing number of examples of genetic polymorphisms affecting drug response in the literature, pharmacogenetic data are rarely used in current clinical practice. The limitations that have prevented the use of pharmacogenetic testing in clinical practice are reviewed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Beutler, E. (1969) Moderne Probleme der Humangenetik. Ergebn. Inn. Mecl. Kinderheilk. 12, 52–125.
Relling, M. V., Hancock, M. L., Rivera, G. K., et al. (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 91(23), 2001–2008.
Veenstra, D. L., Blough, D. K., Higashi, M. K., et al. (2005) CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin. Pharmacol. Ther. 77(5), 353–364.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science, Food and Drug Administration. November 14, 2005 (http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4194S1_Slide-Index.htm).
Rieder, M. J., Reiner, A. P., Gage, B. F., et al. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285–2293.
Sconce, E. A., Khan, T. I., Wynne, H. A., et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7), 2329–2333.
Higashi, M. K., Veenstra, D. L., Kondo, L. M., et al. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13), 1690–1698.
Johnson, J. A., Zineh, I., Puckett, B. J., McGorray, S. P., Yarandi, H. N., and Pauly, D. F. (2003) Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther. 74(1), 44–52.
De Laurentiis, M., Cancello, G., Zinno, L., et al. (2005) Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Ann. Oncol. 16(Suppl 4), iv7–iv13.
Gorre, M. E., Mohammed, M., Ellwood, K., et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531), 876–880.
Lynch, T. J., Bell, D. W., Sordella, R., et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129–2139.
Bossi, P., Peytavin, G., Ait-Mohand, H., et al. (2004) GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med. 5(5), 352–359.
Quirk, E., McLeod, H., and Powderly, W. (2004) The pharmacogenetics of antiretroviral therapy: a review of studies to date. Clin. Infect. Dis. 39(1), 98–106.
US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection A. (2005) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 6, 2005 (http://aidsinfo.nih.gov).
Hirsch, M. S., Brun-Vezinet, F., D’Aquila, R. T., et al. (2000) Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 283(18), 2417–2426.
Goetz, M. P., Rae, J. M, Suman, V. J., et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23(36), 9312–9318.
Gardiner, S. J. and Begg, E. J. (2005) Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet. Genomics 15(5), 365–369.
Zineh, I., Beitelshees, A. L., Gaedigk, A., et al. (2004) Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin. Pharmacol. Ther. 76(6), 536–544.
Evans, W. E., Hon, Y. Y., Bomgaars, L., et al. (2001) Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J. Clin. Oncol 19(8), 2293–2301.
Zineh, I., Gerhard, T., Aquilante, C. L., Beitelshees, A. L., Beasley, B. N., and Hartzema, A. G. (2004) Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J. 4(6), 354–358.
Giardiello, F. M., Brensinger, J. D., Petersen, G. M., et al. (1997) The Use and Interpretation of Commercial APC Gene Testing for Familial Adenomatous Polyposis. N. Engl. J. Med. 336(12), 823–827.
Ginsburg, G. S., Konstance, R. P., Allsbrook, J. S., Schulman, K. A. (2005) Implications of pharmacogenomics for drug development and clinical practice. Arch. Intern. Med. 165(20), 2331–2336.
Logue, L. J. (2003) Genetic testing coverage and reimbursement: a provider’s dilemma. Clin. Leadersh. Manag. Rev. 17(6), 346–350.
Evans, W. E. and McLeod, H. L. (2003) Pharmacogenomics—drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538–549.
US Food and Drug Administration. (2003) Guidance for Industry: Pharmacogenomic Data Submissions 2003 (http://www.fda.gov/cber/gdlns/pharmdtasub.pdf).
Andersson, H. C., Krousel-Wood, M. A., Jackson, K. E., Rice, J., and Lubin, I. M. (2002) Medical genetic test reporting for cystic fibrosis (deltaF508) and factor V Leiden in North American laboratories. Genet. Med. 4(5), 324–327.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Cheang, K.I. (2008). Pharmacogenetics in the Clinic. In: Wu-Pong, S., Rojanasakul, Y. (eds) Biopharmaceutical Drug Design and Development. Humana Press. https://doi.org/10.1007/978-1-59745-532-9_12
Download citation
DOI: https://doi.org/10.1007/978-1-59745-532-9_12
Publisher Name: Humana Press
Print ISBN: 978-1-58829-716-7
Online ISBN: 978-1-59745-532-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)